PremiumThe FlyApogee Therapeutics reports data from Phase 1b trial of APG808 Apogee Therapeutics reports Q1 net loss ($55.3M) vs. ($32.1M) last year 3 Best Stocks to Buy Now, 4/9/2025, According to Top Analysts PremiumRatingsOptimistic Buy Rating for Apogee Therapeutics Driven by Promising Clinical Trial Developments Apogee Therapeutics Reports 2024 Financial Results and Pipeline Progress Apogee Therapeutics price target raised to $116 from $110 at Guggenheim PremiumThe FlyOruka Therapeutics initiated with an Outperform at Wolfe Research Apogee Therapeutics Advances APG777 in Key Phase 2 Trial Apogee announces first patient dosed in Part B of Phase 2 APEX trial 
